سعر اربيمون ام اي 25 مجم 50 كبسولة 2024

Arpimune ME 25 mg soft gelatin capsules (ciclosporin 25 mg, microemulsion formulation), a calcineurin-inhibitor immunosuppressant made by RPG Life Sciences, India, and imported by International Trading Office; pack of 50 capsules (5 strips).

• Prophylaxis of organ rejection in kidney, liver and heart allogeneic transplants, in combination with adrenal corticosteroids and other immunosuppressantsPopulation: Transplant recipients (US label)DailyMed (U.S. National Library of Medicine)
• Severe active rheumatoid arthritis not adequately responsive to methotrexate (alone or with methotrexate)Population: Adults (US label)DailyMed (U.S. National Library of Medicine)
• Severe, recalcitrant plaque psoriasis in non-immunocompromised adults who failed at least one systemic therapy or cannot use other systemic therapiesPopulation: Adults (US label)DailyMed (U.S. National Library of Medicine)

• Principal adverse reactions in transplantation: renal dysfunction, tremor, hirsutism, hypertension and gum hyperplasia; glomerular capillary thrombosis (possibly progressing to graft failure), significant hyperkalemia and hyperuricemia have also been reported.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Known hypersensitivity to cyclosporine or any component.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Rheumatoid arthritis and psoriasis patients with abnormal renal function, uncontrolled hypertension or malignancies.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Psoriasis patients receiving concomitant PUVA or UVB therapy, methotrexate or other immunosuppressants, coal tar or radiation therapy.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Boxed warning: prescribe only by physicians experienced in systemic immunosuppressive therapy; increased susceptibility to infection and possible development of neoplasia (including lymphoma).International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Boxed warning: cyclosporine (modified) has increased bioavailability compared with Sandimmune; the two are not bioequivalent and cannot be interchanged without physician supervision; monitor blood concentrations.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Boxed warning (psoriasis): prior PUVA, methotrexate, other immunosuppressants, UVB, coal tar or radiation increases skin malignancy risk; cyclosporine can cause systemic hypertension and nephrotoxicity, with risk increasing with dose and duration.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Drugs that increase cyclosporine concentrations (diltiazem, nicardipine, verapamil, fluconazole, itraconazole, ketoconazole, voriconazole, azithromycin, clarithromycin, erythromycin, methylprednisolone, allopurinol, amiodarone, bromocriptine, colchicine, danazol, imatinib, metoclopramide, nefazodone, oral contraceptives, HIV protease inhibitors, grapefruit juice)These may increase cyclosporine blood concentrations; monitor levels and adjust the dose.DailyMed (U.S. National Library of Medicine)
• Drugs that decrease cyclosporine concentrations (nafcillin, rifampin, carbamazepine, oxcarbazepine, phenobarbital, phenytoin, bosentan, octreotide, orlistat, sulfinpyrazone, terbinafine, ticlopidine, St John's wort)These may decrease cyclosporine blood concentrations, risking rejection; monitor levels and adjust the dose.DailyMed (U.S. National Library of Medicine)
• HMG-CoA reductase inhibitors (statins)Myotoxicity including muscle pain, weakness, myositis and rhabdomyolysis has been reported with concomitant statins; consider dose reduction or temporary withholding of the statin.DailyMed (U.S. National Library of Medicine)

• Decades of published data (including the Transplant Pregnancy Registry International) have not identified a drug-associated risk of major birth defects or miscarriage; adverse maternal or fetal outcomes including hypertension, preeclampsia, preterm birth and low birth weight have been reported, partly related to the underlying condition. A pregnancy exposure registry (TPRI) is available.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Cyclosporine and its metabolites are present in human milk; adverse effects on breastfed infants have not been reported and effects on milk production are unknown; lactating women should avoid additional alcohol intake.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Ciclosporin: Calcineurin inhibitor: forms a complex with cyclophilin that inhibits calcineurin, suppressing T-lymphocyte activation and production of lymphokines such as interleukin-2 (cell-mediated immunity); does not cause bone marrow suppression (US label).